DC-based immunotherapy to treat Malignant Mesothelioma

Project Information

H2020MM04

Grant agreement ID: 668769

DOI 10.3030/668769

Project closed

EC signature date 1 December 2015

Start date 1 January 2016

End date 31 December 2021

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost € 5 782 965,00

EU contribution € 5 782 965,00

Coordinated by

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Netherlands

Publications

Peer reviewed articles (1)

A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial

Author(s): Robert A. Belderbos, Paul Baas, Rossana Berardi, Robin Cornelissen, Dean A. Fennell, Jan P. van Meerbeeck, Arnaud Scherpereel, Heleen Vroman, Joachim G. J. V. Aerts
Published in: Translational Lung Cancer Research, Issue 8/3, 2019, Page(s) 280-285, ISSN 2218-6751
Publisher: AME publishing company
DOI: 10.21037/tlcr.2019.05.05

Intellectual Property Rights

Patent (2)

METHOD FOR PREPARING AN IMMUNOGENIC LYSATE, THE LYSATE OBTAINED, DENDRITIC CELLS LOADED WITH SUCH LYSATE AND A PHARMACEUTICAL COMPOSITION COMPRISING THE LYSATE OR THE DENDRITIC CELLS

Application/Publication number: EP 13821476
Date: 2013-12-20
Applicant(s): AMPHERA BV

Pharmaceutical composition for use in the treatment of cancer

Application/Publication number: PCT/NL2017/ 050809
Date: 2016-12-02
Applicant(s): AMPHERA BV